samedan logo
 
 
 
spacer
home > ebr > spring 2018 > tomorrows treatment
PUBLICATIONS
European Biopharmaceutical Review

Tomorrows Treatment

Ever since the time of Hippocrates who wrote about the individuality of disease and the necessity of giving different drugs to different patients – “for the sweet ones do not benefit everyone, nor do the astringent ones, nor are all the patients able to drink the same things” – a personalised approach to medicine has been recognised steadily, but it is only in recent decades that a fuller scientific understanding of the approach has become better appreciated.

However, the decoding of the human genome in 2003 saw a step-change in the acceleration of that understanding, and the medical community has long predicted that an era of personalised medicine will soon be ubiquitous. This article examines how that reality is now upon us and that the use of biomarkers and personalised medicine in oncology is transforming current cancer treatments.

New Ideas

While established cancer treatments such as surgery, radiation, and chemotherapy are still improving, excitement in the cancer arena today lies in the development of targeted therapies, otherwise known as ‘personalised medicine’. This individualised approach includes not only the early stage diagnosis of every specific cancer, tailor-made therapeutic intervention, and the careful monitoring of patients’ progress, but also heralds the prospect of personalised treatments that stimulate the body’s immune system to fight cancer.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Tarquin Edwards is a writer, freelance journalist, and advisor to a number of publicly-quoted and private companies in the biotechnology and biopharmaceutical sectors. He is Managing Director of Peckwater PR, a media and IR consultancy, which he founded in 2009. Tarquin has over 20 years’ experience working in the financial PR industry, coordinating and implementing media and IR campaigns on behalf of mid- to smaller-quoted and privately owned companies. He has a Masters degree from Oxford University, UK and a BA (Hons) degree from the University of London (Royal Holloway), UK.
spacer
Tarquin Edwards
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders

July 12, 2020 - The Data Demonstrating Benefits of Pharmacokinetic-Guided Prophylaxis Therapy in Hemophilia and von Willebrand Disease are Among 13 Presentations from Takeda’s Hematology Portfolio and Pipeline
More info >>

White Papers

7 Common Myths about QP Training Debunked: A Guide for Senior Managers

RSSL

The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
More info >>

 
Industry Events

BIO-Europe Digital

26-29 October 2020, Digitally delivered

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement